{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T12:25:06Z","timestamp":1789647906035,"version":"4.0.0"},"reference-count":97,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,3,14]],"date-time":"2023-03-14T00:00:00Z","timestamp":1678752000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,3,14]],"date-time":"2023-03-14T00:00:00Z","timestamp":1678752000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004147","name":"Tsinghua University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004147","id-type":"DOI","asserted-by":"publisher"}]},{"name":"The China Scholarship Council"},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["P30CA047904"],"award-info":[{"award-number":["P30CA047904"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["P30CA047904"],"award-info":[{"award-number":["P30CA047904"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001006","name":"Breast Cancer Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001006","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009634","name":"Susan G. Komen","doi-asserted-by":"publisher","award":["SAC160073"],"award-info":[{"award-number":["SAC160073"]}],"id":[{"id":"10.13039\/100009634","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009634","name":"Susan G. Komen","doi-asserted-by":"publisher","award":["SAC110021"],"award-info":[{"award-number":["SAC110021"]}],"id":[{"id":"10.13039\/100009634","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012639","name":"METAvivor","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012639","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001513","name":"Breast Cancer Alliance","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001513","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>RET, a single-pass receptor tyrosine kinase encoded on human chromosome 10, is well known to the field of developmental biology for its role in the ontogenesis of the central and enteric nervous systems and the kidney. In adults, RET alterations have been characterized as drivers of non-small cell lung cancer and multiple neuroendocrine neoplasms. In breast cancer, RET signaling networks have been shown to influence diverse functions including tumor development, metastasis, and therapeutic resistance. While RET is known to drive the development and progression of multiple solid tumors, therapeutic agents selectively targeting RET are relatively new, though multiple multi-kinase inhibitors have shown promise as RET inhibitors in the past; further, RET has been historically neglected as a potential therapeutic co-target in endocrine-refractory breast cancers despite mounting evidence for a key pathologic role and repeated description of a bi-directional relationship with the estrogen receptor, the principal driver of most breast tumors. Additionally, the recent discovery of RET enrichment in breast cancer brain metastases suggests a role for RET inhibition specific to advanced disease. This review assesses the status of research on RET in breast cancer and evaluates the therapeutic potential of RET-selective kinase inhibitors across major breast cancer subtypes.<\/jats:p>","DOI":"10.1186\/s13058-023-01622-7","type":"journal-article","created":{"date-parts":[[2023,3,14]],"date-time":"2023-03-14T14:06:43Z","timestamp":1678802803000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":34,"title":["RET signaling in breast cancer therapeutic resistance and metastasis"],"prefix":"10.1186","volume":"25","author":[{"given":"Geoffrey","family":"Pecar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simeng","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jagmohan","family":"Hooda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer M.","family":"Atkinson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steffi","family":"Oesterreich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrian V.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,3,14]]},"reference":[{"issue":"3","key":"1622_CR1","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.1046\/j.1471-4159.2000.741175.x","volume":"74","author":"H Sawada","year":"2000","unstructured":"Sawada H, et al. Neuroprotective mechanism of glial cell line-derived neurotrophic factor in mesencephalic neurons. J Neurochem. 2000;74(3):1175\u201384.","journal-title":"J Neurochem"},{"issue":"7","key":"1622_CR2","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1158\/2159-8290.CD-18-0338","volume":"8","author":"V Subbiah","year":"2018","unstructured":"Subbiah V, et al. Precision targeted therapy with BLU-667 for RET-driven cancers. Cancer Discov. 2018;8(7):836\u201349.","journal-title":"Cancer Discov"},{"issue":"4","key":"1622_CR3","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1016\/0092-8674(90)90659-3","volume":"60","author":"M Grieco","year":"1990","unstructured":"Grieco M, et al. PTC is a novel rearranged form of the ret proto-oncogene and is frequently detected in vivo in human thyroid papillary carcinomas. Cell. 1990;60(4):557\u201363.","journal-title":"Cell"},{"issue":"5","key":"1622_CR4","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1530\/ERC-13-0085","volume":"20","author":"ML Gild","year":"2013","unstructured":"Gild ML, et al. Targeting mTOR in RET mutant medullary and differentiated thyroid cancer cells. Endocr Relat Cancer. 2013;20(5):659\u201367.","journal-title":"Endocr Relat Cancer"},{"issue":"29","key":"1622_CR5","doi-asserted-by":"publisher","first-page":"4046","DOI":"10.1038\/s41388-018-0235-y","volume":"37","author":"A Gattelli","year":"2018","unstructured":"Gattelli A, et al. Chronic expression of wild-type Ret receptor in the mammary gland induces luminal tumors that are sensitive to Ret inhibition. Oncogene. 2018;37(29):4046\u201354.","journal-title":"Oncogene"},{"issue":"2","key":"1622_CR6","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1007\/s10549-016-4078-3","volume":"162","author":"M Gardaneh","year":"2017","unstructured":"Gardaneh M, et al. GDNF induces RET-SRC-HER2-dependent growth in trastuzumab-sensitive but SRC-independent growth in resistant breast tumor cells. Breast Cancer Res Treat. 2017;162(2):231\u201341.","journal-title":"Breast Cancer Res Treat"},{"issue":"12","key":"1622_CR7","doi-asserted-by":"publisher","first-page":"3783","DOI":"10.1158\/0008-5472.CAN-12-4265","volume":"73","author":"A Morandi","year":"2013","unstructured":"Morandi A, et al. GDNF-RET signaling in ER-positive breast cancers is a key determinant of response and resistance to aromatase inhibitors. Cancer Res. 2013;73(12):3783\u201395.","journal-title":"Cancer Res"},{"issue":"2","key":"1622_CR8","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1016\/0092-8674(85)90115-1","volume":"42","author":"M Takahashi","year":"1985","unstructured":"Takahashi M, Ritz J, Cooper GM. Activation of a novel human transforming gene, ret, by DNA rearrangement. Cell. 1985;42(2):581\u20138.","journal-title":"Cell"},{"issue":"2","key":"1622_CR9","doi-asserted-by":"publisher","first-page":"a009134","DOI":"10.1101\/cshperspect.a009134","volume":"5","author":"CF Ibanez","year":"2013","unstructured":"Ibanez CF. Structure and physiology of the RET receptor tyrosine kinase. Cold Spring Harb Perspect Biol. 2013;5(2):a009134.","journal-title":"Cold Spring Harb Perspect Biol"},{"issue":"12","key":"1622_CR10","doi-asserted-by":"publisher","first-page":"3319","DOI":"10.1016\/j.celrep.2016.11.061","volume":"17","author":"I Plaza-Menacho","year":"2016","unstructured":"Plaza-Menacho I, et al. RET functions as a dual-specificity kinase that requires allosteric inputs from juxtamembrane elements. Cell Rep. 2016;17(12):3319\u201332.","journal-title":"Cell Rep"},{"issue":"14","key":"1622_CR11","doi-asserted-by":"publisher","first-page":"14213","DOI":"10.1074\/jbc.M312600200","volume":"279","author":"Y Kawamoto","year":"2004","unstructured":"Kawamoto Y, et al. Identification of RET autophosphorylation sites by mass spectrometry. J Biol Chem. 2004;279(14):14213\u201324.","journal-title":"J Biol Chem"},{"issue":"19","key":"1622_CR12","doi-asserted-by":"publisher","first-page":"3838","DOI":"10.1091\/mbc.e12-02-0114","volume":"23","author":"DS Richardson","year":"2012","unstructured":"Richardson DS, et al. Alternative splicing results in RET isoforms with distinct trafficking properties. Mol Biol Cell. 2012;23(19):3838\u201350.","journal-title":"Mol Biol Cell"},{"issue":"10","key":"1622_CR13","doi-asserted-by":"publisher","first-page":"3743","DOI":"10.1158\/0008-5472.CAN-07-5100","volume":"68","author":"A Boulay","year":"2008","unstructured":"Boulay A, et al. The Ret receptor tyrosine kinase pathway functionally interacts with the ERalpha pathway in breast cancer. Cancer Res. 2008;68(10):3743\u201351.","journal-title":"Cancer Res"},{"issue":"3\u20134","key":"1622_CR14","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1159\/000059341","volume":"95","author":"MT Carter","year":"2001","unstructured":"Carter MT, et al. Conservation of RET proto-oncogene splicing variants and implications for RET isoform function. Cytogenet Cell Genet. 2001;95(3\u20134):169\u201376.","journal-title":"Cytogenet Cell Genet"},{"issue":"1","key":"1622_CR15","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/S0959-4388(99)00048-3","volume":"10","author":"RH Baloh","year":"2000","unstructured":"Baloh RH, et al. The GDNF family ligands and receptors\u2014implications for neural development. Curr Opin Neurobiol. 2000;10(1):103\u201310.","journal-title":"Curr Opin Neurobiol"},{"issue":"3","key":"1622_CR16","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1007\/PL00005711","volume":"115","author":"CA Nosrat","year":"1997","unstructured":"Nosrat CA, et al. Cellular and developmental patterns of expression of Ret and glial cell line-derived neurotrophic factor receptor alpha mRNAs. Exp Brain Res. 1997;115(3):410\u201322.","journal-title":"Exp Brain Res"},{"issue":"1","key":"1622_CR17","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.neo.2017.10.010","volume":"20","author":"GC Fielder","year":"2018","unstructured":"Fielder GC, et al. The GDNF family: A role in cancer? Neoplasia. 2018;20(1):99\u2013117.","journal-title":"Neoplasia"},{"issue":"24","key":"1622_CR18","doi-asserted-by":"publisher","first-page":"6968","DOI":"10.1046\/j.1432-1327.2000.01826.x","volume":"267","author":"M Saarma","year":"2000","unstructured":"Saarma M. GDNF\u2014A stranger in the TGF-beta superfamily? Eur J Biochem. 2000;267(24):6968\u201371.","journal-title":"Eur J Biochem"},{"key":"1622_CR19","doi-asserted-by":"publisher","first-page":"1873","DOI":"10.3389\/fphys.2018.01873","volume":"9","author":"LM Mulligan","year":"2018","unstructured":"Mulligan LM. GDNF and the RET receptor in cancer: new insights and therapeutic potential. Front Physiol. 2018;9:1873.","journal-title":"Front Physiol"},{"issue":"3","key":"1622_CR20","doi-asserted-by":"publisher","first-page":"112","DOI":"10.2183\/pjab.98.008","volume":"98","author":"M Takahashi","year":"2022","unstructured":"Takahashi M. RET receptor signaling: function in development, metabolic disease, and cancer. Proc Jpn Acad Ser B Phys Biol Sci. 2022;98(3):112\u201325.","journal-title":"Proc Jpn Acad Ser B Phys Biol Sci"},{"issue":"4\u20135","key":"1622_CR21","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1016\/j.cytogfr.2005.05.010","volume":"16","author":"E Arighi","year":"2005","unstructured":"Arighi E, Borrello MG, Sariola H. RET tyrosine kinase signaling in development and cancer. Cytokine Growth Factor Rev. 2005;16(4\u20135):441\u201367.","journal-title":"Cytokine Growth Factor Rev"},{"issue":"1","key":"1622_CR22","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1007\/s00441-020-03262-1","volume":"382","author":"K Kawai","year":"2020","unstructured":"Kawai K, Takahashi M. Intracellular RET signaling pathways activated by GDNF. Cell Tissue Res. 2020;382(1):113\u201323.","journal-title":"Cell Tissue Res"},{"issue":"45","key":"1622_CR23","doi-asserted-by":"publisher","first-page":"6546","DOI":"10.1038\/sj.onc.1210480","volume":"26","author":"S Donatello","year":"2007","unstructured":"Donatello S, et al. SH2B1beta adaptor is a key enhancer of RET tyrosine kinase signaling. Oncogene. 2007;26(45):6546\u201359.","journal-title":"Oncogene"},{"issue":"18","key":"1622_CR24","doi-asserted-by":"publisher","first-page":"18262","DOI":"10.1074\/jbc.M400505200","volume":"279","author":"M Encinas","year":"2004","unstructured":"Encinas M, et al. Tyrosine 981, a novel ret autophosphorylation site, binds c-Src to mediate neuronal survival. J Biol Chem. 2004;279(18):18262\u20139.","journal-title":"J Biol Chem"},{"issue":"2","key":"1622_CR25","doi-asserted-by":"publisher","first-page":"e31258","DOI":"10.1371\/journal.pone.0031258","volume":"7","author":"TK Lundgren","year":"2012","unstructured":"Lundgren TK, et al. RET PLCgamma phosphotyrosine binding domain regulates Ca2+ signaling and neocortical neuronal migration. PLoS ONE. 2012;7(2):e31258.","journal-title":"PLoS ONE"},{"issue":"3","key":"1622_CR26","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1172\/JCI41619","volume":"120","author":"S Jain","year":"2010","unstructured":"Jain S, et al. Organotypic specificity of key RET adaptor-docking sites in the pathogenesis of neurocristopathies and renal malformations in mice. J Clin Investig. 2010;120(3):778\u201390.","journal-title":"J Clin Investig"},{"issue":"44","key":"1622_CR27","doi-asserted-by":"publisher","first-page":"33577","DOI":"10.1074\/jbc.M605604200","volume":"281","author":"PP Knowles","year":"2006","unstructured":"Knowles PP, et al. Structure and chemical inhibition of the RET tyrosine kinase domain. J Biol Chem. 2006;281(44):33577\u201387.","journal-title":"J Biol Chem"},{"issue":"13","key":"1622_CR28","doi-asserted-by":"publisher","first-page":"4177","DOI":"10.1128\/MCB.21.13.4177-4187.2001","volume":"21","author":"RM Melillo","year":"2001","unstructured":"Melillo RM, et al. Docking protein FRS2 links the protein tyrosine kinase RET and its oncogenic forms with the mitogen-activated protein kinase signaling cascade. Mol Cell Biol. 2001;21(13):4177\u201387.","journal-title":"Mol Cell Biol"},{"issue":"14","key":"1622_CR29","first-page":"3727","volume":"60","author":"G De Vita","year":"2000","unstructured":"De Vita G, et al. Tyrosine 1062 of RET-MEN2A mediates activation of Akt (protein kinase B) and mitogen-activated protein kinase pathways leading to PC12 cell survival. Cancer Res. 2000;60(14):3727\u201331.","journal-title":"Cancer Res"},{"issue":"50","key":"1622_CR30","doi-asserted-by":"publisher","first-page":"39159","DOI":"10.1074\/jbc.M006908200","volume":"275","author":"V Besset","year":"2000","unstructured":"Besset V, Scott RP, Ibanez CF. Signaling complexes and protein-protein interactions involved in the activation of the Ras and phosphatidylinositol 3-kinase pathways by the c-Ret receptor tyrosine kinase. J Biol Chem. 2000;275(50):39159\u201366.","journal-title":"J Biol Chem"},{"issue":"1","key":"1622_CR31","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1615\/JEnvironPatholToxicolOncol.2018028386","volume":"38","author":"H Lu","year":"2019","unstructured":"Lu H, et al. Mitogen-activated protein kinase (MAPK): new insights in breast cancer. J Environ Pathol Toxicol Oncol. 2019;38(1):51\u20139.","journal-title":"J Environ Pathol Toxicol Oncol"},{"issue":"Suppl 1","key":"1622_CR32","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1634\/theoncologist.2011-S1-12","volume":"16","author":"J Baselga","year":"2011","unstructured":"Baselga J. Targeting the phosphoinositide-3 (PI3) kinase pathway in breast cancer. Oncologist. 2011;16(Suppl 1):12\u20139.","journal-title":"Oncologist"},{"issue":"3","key":"1622_CR33","first-page":"305","volume":"5","author":"V Avantaggiato","year":"1994","unstructured":"Avantaggiato V, et al. Developmental expression of the RET protooncogene. Cell Growth Differ. 1994;5(3):305\u201311.","journal-title":"Cell Growth Differ"},{"issue":"20","key":"1622_CR34","doi-asserted-by":"publisher","first-page":"3963","DOI":"10.1242\/dev.128.20.3963","volume":"128","author":"H Enomoto","year":"2001","unstructured":"Enomoto H, et al. RET signaling is essential for migration, axonal growth and axon guidance of developing sympathetic neurons. Development. 2001;128(20):3963\u201374.","journal-title":"Development"},{"key":"1622_CR35","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2019\/1036907","volume":"2019","author":"EV Mitroshina","year":"2019","unstructured":"Mitroshina EV, Mishchenko TA, Shirokova OM, Astrakhanova TA, Loginova MM, Epifanova EA, Babaev AA, Tarabykin VS, Vedunova MV. Intracellular neuroprotective mechanisms in neuron-glial networks mediated by glial cell line-derived neurotrophic factor. Oxid Med Cell Longev. 2019;2019:1\u201315.","journal-title":"Oxid Med Cell Longev"},{"issue":"8","key":"1622_CR36","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1007\/s00383-015-3731-y","volume":"31","author":"C Tomuschat","year":"2015","unstructured":"Tomuschat C, Puri P. RET gene is a major risk factor for Hirschsprung\u2019s disease: a meta-analysis. Pediatr Surg Int. 2015;31(8):701\u201310.","journal-title":"Pediatr Surg Int"},{"issue":"7","key":"1622_CR37","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1038\/gim.2017.178","volume":"20","author":"Q Jiang","year":"2018","unstructured":"Jiang Q, et al. RET somatic mutations are underrecognized in Hirschsprung disease. Genet Med. 2018;20(7):770\u20137.","journal-title":"Genet Med"},{"issue":"21","key":"1622_CR38","doi-asserted-by":"publisher","first-page":"5503","DOI":"10.1242\/dev.01421","volume":"131","author":"S Jain","year":"2004","unstructured":"Jain S, et al. Mice expressing a dominant-negative Ret mutation phenocopy human Hirschsprung disease and delineate a direct role of Ret in spermatogenesis. Development. 2004;131(21):5503\u201313.","journal-title":"Development"},{"issue":"6461","key":"1622_CR39","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1038\/367380a0","volume":"367","author":"A Schuchardt","year":"1994","unstructured":"Schuchardt A, et al. Defects in the kidney and enteric nervous system of mice lacking the tyrosine kinase receptor Ret. Nature. 1994;367(6461):380\u20133.","journal-title":"Nature"},{"issue":"3","key":"1622_CR40","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1242\/dmm.049286","volume":"15","author":"SA Vallone","year":"2022","unstructured":"Vallone SA, et al. Aberrant RET expression affects normal mammary gland post-lactation transition, enhancing cancer potential. Dis Model Mech. 2022;15(3):1\u201314.","journal-title":"Dis Model Mech"},{"issue":"1","key":"1622_CR41","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1007\/s10911-020-09445-4","volume":"25","author":"A Gattelli","year":"2020","unstructured":"Gattelli A, et al. Ret receptor has distinct alterations and functions in breast cancer. J Mammary Gland Biol Neoplasia. 2020;25(1):13\u201326.","journal-title":"J Mammary Gland Biol Neoplasia"},{"issue":"1","key":"1622_CR42","doi-asserted-by":"publisher","first-page":"4821","DOI":"10.1038\/s41467-018-07341-4","volume":"9","author":"BS Paratala","year":"2018","unstructured":"Paratala BS, et al. RET rearrangements are actionable alterations in breast cancer. Nat Commun. 2018;9(1):4821.","journal-title":"Nat Commun"},{"key":"1622_CR43","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.cancergen.2019.07.002","volume":"238","author":"JI Staubitz","year":"2019","unstructured":"Staubitz JI, et al. ANKRD26-RET\u2014a novel gene fusion involving RET in papillary thyroid carcinoma. Cancer Genet. 2019;238:10\u20137.","journal-title":"Cancer Genet"},{"issue":"1","key":"1622_CR44","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.ccell.2017.12.004","volume":"33","author":"R Yaeger","year":"2018","unstructured":"Yaeger R, et al. Clinical sequencing defines the genomic landscape of metastatic colorectal cancer. Cancer Cell. 2018;33(1):125\u201336.","journal-title":"Cancer Cell"},{"issue":"30","key":"1622_CR45","doi-asserted-by":"publisher","first-page":"28929","DOI":"10.18632\/oncotarget.4325","volume":"6","author":"AF Le Rolle","year":"2015","unstructured":"Le Rolle AF, et al. Identification and characterization of RET fusions in advanced colorectal cancer. Oncotarget. 2015;6(30):28929\u201337.","journal-title":"Oncotarget"},{"key":"1622_CR46","doi-asserted-by":"publisher","first-page":"4846","DOI":"10.1038\/ncomms5846","volume":"5","author":"N Stransky","year":"2014","unstructured":"Stransky N, et al. The landscape of kinase fusions in cancer. Nat Commun. 2014;5:4846.","journal-title":"Nat Commun"},{"issue":"3","key":"1622_CR47","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1038\/nm.2673","volume":"18","author":"D Lipson","year":"2012","unstructured":"Lipson D, et al. Identification of new ALK and RET gene fusions from colorectal and lung cancer biopsies. Nat Med. 2012;18(3):382\u20134.","journal-title":"Nat Med"},{"issue":"3","key":"1622_CR48","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1038\/nm.2658","volume":"18","author":"K Takeuchi","year":"2012","unstructured":"Takeuchi K, et al. RET, ROS1 and ALK fusions in lung cancer. Nat Med. 2012;18(3):378\u201381.","journal-title":"Nat Med"},{"issue":"10","key":"1622_CR49","doi-asserted-by":"publisher","first-page":"2510","DOI":"10.1002\/ijc.29974","volume":"138","author":"R Hatem","year":"2016","unstructured":"Hatem R, et al. Vandetanib as a potential new treatment for estrogen receptor-negative breast cancers. Int J Cancer. 2016;138(10):2510\u201321.","journal-title":"Int J Cancer"},{"issue":"13","key":"1622_CR50","doi-asserted-by":"publisher","first-page":"4287","DOI":"10.1245\/s10434-015-4597-x","volume":"22","author":"PM Spanheimer","year":"2015","unstructured":"Spanheimer PM, et al. Receptor tyrosine kinase expression predicts response to sunitinib in breast cancer. Ann Surg Oncol. 2015;22(13):4287\u201394.","journal-title":"Ann Surg Oncol"},{"issue":"7","key":"1622_CR51","doi-asserted-by":"publisher","first-page":"2750","DOI":"10.1172\/JCI45014","volume":"121","author":"BD Lehmann","year":"2011","unstructured":"Lehmann BD, et al. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Investig. 2011;121(7):2750\u201367.","journal-title":"J Clin Investig"},{"issue":"8","key":"1622_CR52","doi-asserted-by":"publisher","first-page":"1988","DOI":"10.1158\/1078-0432.CCR-16-1679","volume":"23","author":"S Kato","year":"2017","unstructured":"Kato S, et al. RET aberrations in diverse cancers: next-generation sequencing of 4,871 patients. Clin Cancer Res. 2017;23(8):1988\u201397.","journal-title":"Clin Cancer Res"},{"issue":"8","key":"1622_CR53","doi-asserted-by":"publisher","first-page":"1640","DOI":"10.1038\/s41591-022-01931-y","volume":"28","author":"V Subbiah","year":"2022","unstructured":"Subbiah V, et al. Pan-cancer efficacy of pralsetinib in patients with RET fusion-positive solid tumors from the phase 1\/2 ARROW trial. Nat Med. 2022;28(8):1640\u20135.","journal-title":"Nat Med"},{"issue":"4","key":"1622_CR54","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1097\/PAS.0000000000000952","volume":"42","author":"I Weinreb","year":"2018","unstructured":"Weinreb I, et al. Recurrent RET gene rearrangements in intraductal carcinomas of salivary gland. Am J Surg Pathol. 2018;42(4):442\u201352.","journal-title":"Am J Surg Pathol"},{"issue":"15_suppl","key":"1622_CR55","doi-asserted-by":"publisher","first-page":"e18023","DOI":"10.1200\/JCO.2021.39.15_suppl.e18023","volume":"39","author":"S Kutukova","year":"2021","unstructured":"Kutukova S, et al. NTRK, ALK and RET rearrangements in salivary gland cancer. J Clin Oncol. 2021;39(15_suppl):e18023.","journal-title":"J Clin Oncol"},{"issue":"1","key":"1622_CR56","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1186\/s12885-018-5262-0","volume":"19","author":"R Mechera","year":"2019","unstructured":"Mechera R, et al. Expression of RET is associated with Oestrogen receptor expression but lacks prognostic significance in breast cancer. BMC Cancer. 2019;19(1):41.","journal-title":"BMC Cancer"},{"issue":"19","key":"1622_CR57","doi-asserted-by":"publisher","first-page":"3746","DOI":"10.1093\/hmg\/ddr291","volume":"20","author":"ZE Stine","year":"2011","unstructured":"Stine ZE, et al. Steroid hormone modulation of RET through two estrogen responsive enhancers in breast cancer. Hum Mol Genet. 2011;20(19):3746\u201356.","journal-title":"Hum Mol Genet"},{"issue":"33","key":"1622_CR58","doi-asserted-by":"publisher","first-page":"4648","DOI":"10.1038\/onc.2010.209","volume":"29","author":"I Plaza-Menacho","year":"2010","unstructured":"Plaza-Menacho I, et al. Targeting the receptor tyrosine kinase RET sensitizes breast cancer cells to tamoxifen treatment and reveals a role for RET in endocrine resistance. Oncogene. 2010;29(33):4648\u201357.","journal-title":"Oncogene"},{"issue":"4","key":"1622_CR59","doi-asserted-by":"publisher","first-page":"e0194023","DOI":"10.1371\/journal.pone.0194023","volume":"13","author":"S Horibata","year":"2018","unstructured":"Horibata S, et al. ER-positive breast cancer cells are poised for RET-mediated endocrine resistance. PLoS ONE. 2018;13(4):e0194023.","journal-title":"PLoS ONE"},{"issue":"2","key":"1622_CR60","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1007\/s10549-011-1775-9","volume":"133","author":"C Wang","year":"2012","unstructured":"Wang C, et al. The rearranged during transfection\/papillary thyroid carcinoma tyrosine kinase is an estrogen-dependent gene required for the growth of estrogen receptor positive breast cancer cells. Breast Cancer Res Treat. 2012;133(2):487\u2013500.","journal-title":"Breast Cancer Res Treat"},{"issue":"8","key":"1622_CR61","doi-asserted-by":"publisher","first-page":"2115","DOI":"10.1158\/1078-0432.CCR-13-2221","volume":"20","author":"PM Spanheimer","year":"2014","unstructured":"Spanheimer PM, et al. Inhibition of RET increases the efficacy of antiestrogen and is a novel treatment strategy for luminal breast cancer. Clin Cancer Res. 2014;20(8):2115\u201325.","journal-title":"Clin Cancer Res"},{"issue":"11","key":"1622_CR62","doi-asserted-by":"publisher","first-page":"1386","DOI":"10.1111\/j.1365-2826.2012.02348.x","volume":"24","author":"FL Campos","year":"2012","unstructured":"Campos FL, et al. GDNF contributes to oestrogen-mediated protection of midbrain dopaminergic neurones. J Neuroendocrinol. 2012;24(11):1386\u201397.","journal-title":"J Neuroendocrinol"},{"issue":"22","key":"1622_CR63","doi-asserted-by":"publisher","first-page":"3228","DOI":"10.1038\/onc.2010.71","volume":"29","author":"J Kang","year":"2010","unstructured":"Kang J, et al. Artemin is estrogen regulated and mediates antiestrogen resistance in mammary carcinoma. Oncogene. 2010;29(22):3228\u201340.","journal-title":"Oncogene"},{"issue":"6","key":"1622_CR64","first-page":"F938","volume":"275","author":"E Moreau","year":"1998","unstructured":"Moreau E, et al. Regulation of c-ret expression by retinoic acid in rat metanephros: implication in nephron mass control. Am J Physiol. 1998;275(6):F938\u201345.","journal-title":"Am J Physiol"},{"key":"1622_CR65","doi-asserted-by":"publisher","DOI":"10.1128\/MCB.00417-18","author":"KT Helzer","year":"2019","unstructured":"Helzer KT, et al. The phosphorylated estrogen receptor alpha (ER) cistrome identifies a subset of active enhancers enriched for direct ER-DNA binding and the transcription factor GRHL2. Mol Cell Biol. 2019. https:\/\/doi.org\/10.1128\/MCB.00417-18.","journal-title":"Mol Cell Biol"},{"key":"1622_CR66","doi-asserted-by":"publisher","first-page":"232435","DOI":"10.4061\/2011\/232435","volume":"2011","author":"R de Leeuw","year":"2011","unstructured":"de Leeuw R, Neefjes J, Michalides R. A role for estrogen receptor phosphorylation in the resistance to tamoxifen. Int J Breast Cancer. 2011;2011:232435.","journal-title":"Int J Breast Cancer"},{"issue":"3","key":"1622_CR67","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1677\/erc.1.01123","volume":"13","author":"N Sarwar","year":"2006","unstructured":"Sarwar N, et al. Phosphorylation of ERalpha at serine 118 in primary breast cancer and in tamoxifen-resistant tumours is indicative of a complex role for ERalpha phosphorylation in breast cancer progression. Endocr Relat Cancer. 2006;13(3):851\u201361.","journal-title":"Endocr Relat Cancer"},{"issue":"49","key":"1622_CR68","doi-asserted-by":"publisher","first-page":"80543","DOI":"10.18632\/oncotarget.11826","volume":"7","author":"E Andreucci","year":"2016","unstructured":"Andreucci E, et al. Targeting the receptor tyrosine kinase RET in combination with aromatase inhibitors in ER positive breast cancer xenografts. Oncotarget. 2016;7(49):80543\u201353.","journal-title":"Oncotarget"},{"issue":"19","key":"1622_CR69","doi-asserted-by":"publisher","first-page":"2034","DOI":"10.1038\/onc.2009.66","volume":"28","author":"J Kang","year":"2009","unstructured":"Kang J, et al. Artemin is oncogenic for human mammary carcinoma cells. Oncogene. 2009;28(19):2034\u201345.","journal-title":"Oncogene"},{"issue":"24","key":"1622_CR70","doi-asserted-by":"publisher","first-page":"7485","DOI":"10.1158\/1078-0432.CCR-19-1129","volume":"25","author":"MF Leal","year":"2019","unstructured":"Leal MF, et al. Early enrichment of ESR1 mutations and the impact on gene expression in presurgical primary breast cancer treated with aromatase inhibitors. Clin Cancer Res. 2019;25(24):7485\u201396.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"1622_CR71","doi-asserted-by":"publisher","first-page":"1865","DOI":"10.1038\/s41467-017-01864-y","volume":"8","author":"LA Martin","year":"2017","unstructured":"Martin LA, et al. Discovery of naturally occurring ESR1 mutations in breast cancer cell lines modelling endocrine resistance. Nat Commun. 2017;8(1):1865.","journal-title":"Nat Commun"},{"issue":"4 Supplement","key":"1622_CR72","doi-asserted-by":"publisher","first-page":"P6-04-04","DOI":"10.1158\/1538-7445.SABCS19-P6-04-04","volume":"80","author":"X Gou","year":"2020","unstructured":"Gou X, et al. Abstract P6\u201304-04: functional characterization of ESR1 fusions in breast cancer. Cancer Res. 2020;80(4 Supplement):P6-04\u201304.","journal-title":"Cancer Res"},{"issue":"19","key":"1622_CR73","doi-asserted-by":"publisher","first-page":"17292","DOI":"10.1074\/jbc.M110.168500","volume":"286","author":"I Plaza-Menacho","year":"2011","unstructured":"Plaza-Menacho I, et al. Focal adhesion kinase (FAK) binds RET kinase via its FERM domain, priming a direct and reciprocal RET-FAK transactivation mechanism. J Biol Chem. 2011;286(19):17292\u2013302.","journal-title":"J Biol Chem"},{"issue":"11","key":"1622_CR74","first-page":"2496","volume":"42","author":"L You","year":"2001","unstructured":"You L, Ebner S, Kruse FE. Glial cell-derived neurotrophic factor (GDNF)-induced migration and signal transduction in corneal epithelial cells. Invest Ophthalmol Vis Sci. 2001;42(11):2496\u2013504.","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"9","key":"1622_CR75","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1002\/emmm.201302625","volume":"5","author":"A Gattelli","year":"2013","unstructured":"Gattelli A, et al. Ret inhibition decreases growth and metastatic potential of estrogen receptor positive breast cancer cells. EMBO Mol Med. 2013;5(9):1335\u201350.","journal-title":"EMBO Mol Med"},{"issue":"8","key":"1622_CR76","doi-asserted-by":"publisher","first-page":"1795","DOI":"10.1158\/1078-0432.CCR-17-3351","volume":"24","author":"S Kabraji","year":"2018","unstructured":"Kabraji S, et al. Drug resistance in HER2-positive breast cancer brain metastases: Blame the barrier or the brain? Clin Cancer Res. 2018;24(8):1795\u2013804.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"1622_CR77","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/s13058-015-0665-1","volume":"18","author":"I Witzel","year":"2016","unstructured":"Witzel I, et al. Breast cancer brain metastases: biology and new clinical perspectives. Breast Cancer Res. 2016;18(1):8.","journal-title":"Breast Cancer Res"},{"issue":"3","key":"1622_CR78","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1007\/s10549-017-4466-3","volume":"166","author":"G Frisk","year":"2017","unstructured":"Frisk G, et al. Survival and level of care among breast cancer patients with brain metastases treated with whole brain radiotherapy. Breast Cancer Res Treat. 2017;166(3):887\u201396.","journal-title":"Breast Cancer Res Treat"},{"issue":"5","key":"1622_CR79","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1001\/jamaoncol.2016.5630","volume":"3","author":"N Priedigkeit","year":"2017","unstructured":"Priedigkeit N, et al. Intrinsic subtype switching and acquired ERBB2\/HER2 amplifications and mutations in breast cancer brain metastases. JAMA Oncol. 2017;3(5):666\u201371.","journal-title":"JAMA Oncol"},{"issue":"4","key":"1622_CR80","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1093\/jnci\/djy110","volume":"111","author":"D Vareslija","year":"2019","unstructured":"Vareslija D, et al. Transcriptome characterization of matched primary breast and brain metastatic tumors to detect novel actionable targets. J Natl Cancer Inst. 2019;111(4):388\u201398.","journal-title":"J Natl Cancer Inst"},{"issue":"1","key":"1622_CR81","first-page":"263","volume":"44","author":"LH Tetri","year":"2020","unstructured":"Tetri LH, et al. RET receptor expression and interaction with TRK receptors in neuroblastomas. Oncol Rep. 2020;44(1):263\u201372.","journal-title":"Oncol Rep"},{"issue":"1","key":"1622_CR82","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1186\/s13058-017-0844-3","volume":"19","author":"C Choy","year":"2017","unstructured":"Choy C, et al. Cooperation of neurotrophin receptor TrkB and Her2 in breast cancer cells facilitates brain metastases. Breast Cancer Res. 2017;19(1):51.","journal-title":"Breast Cancer Res"},{"issue":"1","key":"1622_CR83","doi-asserted-by":"publisher","first-page":"16103","DOI":"10.1038\/s41598-021-95612-4","volume":"11","author":"M Moccia","year":"2021","unstructured":"Moccia M, et al. Targeted activity of the small molecule kinase inhibitor Pz-1 towards RET and TRK kinases. Sci Rep. 2021;11(1):16103.","journal-title":"Sci Rep"},{"key":"1622_CR84","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.1016\/j.biopha.2018.09.177","volume":"108","author":"A Masjedi","year":"2018","unstructured":"Masjedi A, et al. The significant role of interleukin-6 and its signaling pathway in the immunopathogenesis and treatment of breast cancer. Biomed Pharmacother. 2018;108:1415\u201324.","journal-title":"Biomed Pharmacother"},{"issue":"4","key":"1622_CR85","doi-asserted-by":"publisher","first-page":"R69","DOI":"10.1186\/bcr3684","volume":"16","author":"B Jovanovic","year":"2014","unstructured":"Jovanovic B, et al. Transforming growth factor beta receptor type III is a tumor promoter in mesenchymal-stem like triple negative breast cancer. Breast Cancer Res. 2014;16(4):R69.","journal-title":"Breast Cancer Res"},{"issue":"1","key":"1622_CR86","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1089\/jir.2014.0026","volume":"35","author":"M Esquivel-Velazquez","year":"2015","unstructured":"Esquivel-Velazquez M, et al. The role of cytokines in breast cancer development and progression. J Interferon Cytokine Res. 2015;35(1):1\u201316.","journal-title":"J Interferon Cytokine Res"},{"issue":"15","key":"1622_CR87","doi-asserted-by":"publisher","first-page":"3309","DOI":"10.1097\/00001756-199710200-00023","volume":"8","author":"E Appel","year":"1997","unstructured":"Appel E, et al. Regulation of GDNF expression in cultured astrocytes by inflammatory stimuli. NeuroReport. 1997;8(15):3309\u201312.","journal-title":"NeuroReport"},{"issue":"1","key":"1622_CR88","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.nbd.2006.08.019","volume":"25","author":"A Saavedra","year":"2007","unstructured":"Saavedra A, Baltazar G, Duarte EP. Interleukin-1beta mediates GDNF up-regulation upon dopaminergic injury in ventral midbrain cell cultures. Neurobiol Dis. 2007;25(1):92\u2013104.","journal-title":"Neurobiol Dis"},{"issue":"24","key":"1622_CR89","doi-asserted-by":"publisher","first-page":"11732","DOI":"10.1158\/0008-5472.CAN-07-2343","volume":"67","author":"S Esseghir","year":"2007","unstructured":"Esseghir S, et al. A role for glial cell derived neurotrophic factor induced expression by inflammatory cytokines and RET\/GFR alpha 1 receptor up-regulation in breast cancer. Cancer Res. 2007;67(24):11732\u201341.","journal-title":"Cancer Res"},{"issue":"4","key":"1622_CR90","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1158\/2159-8290.CD-19-1116","volume":"10","author":"V Subbiah","year":"2020","unstructured":"Subbiah V, Cote GJ. Advances in targeting RET-dependent cancers. Cancer Discov. 2020;10(4):498\u2013505.","journal-title":"Cancer Discov"},{"issue":"11","key":"1622_CR91","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.1200\/JCO.19.02551","volume":"38","author":"V Subbiah","year":"2020","unstructured":"Subbiah V, et al. State-of-the-art strategies for targeting RET-dependent cancers. J Clin Oncol. 2020;38(11):1209\u201321.","journal-title":"J Clin Oncol"},{"issue":"8","key":"1622_CR92","doi-asserted-by":"publisher","first-page":"1869","DOI":"10.1093\/annonc\/mdy137","volume":"29","author":"V Subbiah","year":"2018","unstructured":"Subbiah V, et al. Selective RET kinase inhibition for patients with RET-altered cancers. Ann Oncol. 2018;29(8):1869\u201376.","journal-title":"Ann Oncol"},{"issue":"15","key":"1622_CR93","doi-asserted-by":"publisher","first-page":"4160","DOI":"10.1158\/1078-0432.CCR-21-0800","volume":"27","author":"V Subbiah","year":"2021","unstructured":"Subbiah V, et al. Intracranial efficacy of selpercatinib in RET fusion-positive non-small cell lung cancers on the LIBRETTO-001 trial. Clin Cancer Res. 2021;27(15):4160\u20137.","journal-title":"Clin Cancer Res"},{"key":"1622_CR94","doi-asserted-by":"crossref","unstructured":"Watanabe, S., et al., Complete Response to Selective RET Inhibition With Selpercatinib (LOXO-292) in a Patient With RET Fusion-Positive Breast Cancer. JCO Precis Oncol, 2021. 5.","DOI":"10.1200\/PO.20.00282"},{"key":"1622_CR95","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1016\/j.annonc.2020.10.599","volume":"32","author":"V Subbiah","year":"2020","unstructured":"Subbiah V, et al. Structural basis of acquired resistance to selpercatinib and pralsetinib mediated by non-gatekeeper RET mutations. Ann Oncol. 2020;32:261\u20138.","journal-title":"Ann Oncol"},{"issue":"4","key":"1622_CR96","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1016\/j.jtho.2020.01.006","volume":"15","author":"BJ Solomon","year":"2020","unstructured":"Solomon BJ, et al. RET solvent front mutations mediate acquired resistance to selective RET inhibition in RET-driven malignancies. J Thorac Oncol. 2020;15(4):541\u20139.","journal-title":"J Thorac Oncol"},{"issue":"15_suppl","key":"1622_CR97","doi-asserted-by":"publisher","first-page":"9516","DOI":"10.1200\/JCO.2020.38.15_suppl.9516","volume":"38","author":"V Subbiah","year":"2020","unstructured":"Subbiah V, et al. Intracranial activity of selpercatinib (LOXO-292) in RET fusion-positive non-small cell lung cancer (NSCLC) patients on the LIBRETTO-001 trial. J Clin Oncol. 2020;38(15_suppl):9516\u20139516.","journal-title":"J Clin Oncol"}],"container-title":["Breast Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13058-023-01622-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13058-023-01622-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13058-023-01622-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,14]],"date-time":"2023-03-14T14:10:49Z","timestamp":1678803049000},"score":1,"resource":{"primary":{"URL":"https:\/\/breast-cancer-research.biomedcentral.com\/articles\/10.1186\/s13058-023-01622-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,14]]},"references-count":97,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["1622"],"URL":"https:\/\/doi.org\/10.1186\/s13058-023-01622-7","relation":{},"ISSN":["1465-542X"],"issn-type":[{"value":"1465-542X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,14]]},"assertion":[{"value":"23 May 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 February 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 March 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"26"}}